Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05 2021 - 4:05PM
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global
biopharmaceutical company and leader in targeted C3 therapies,
today announced that the company approved the grant of equity
awards to two new employees with grant date of March 1, 2021, as
equity inducement awards outside of the company's 2017 Stock
Incentive Plan (but under the terms of the 2021 Inducement Stock
Incentive Plan) and material to the employees’ acceptance of
employment with the company. The equity awards were approved in
accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received options to purchase 33,650 shares of
Apellis common stock and 825 restricted stock units (RSUs). The
options have an exercise price of $47.68, which is equal to the
closing price of Apellis common stock on March 1, 2021, the grant
date of the options. One-fourth of the shares underlying the
employee options will vest on the one year anniversary of the grant
date and thereafter 1/48th of the shares underlying the employee
options will vest monthly, such that the shares underlying the
options granted to the employees will be fully vested on the fourth
anniversary of the grant date, subject to the employees’ continued
employment with Apellis on such vesting dates. Each RSU will vest
as to 25% of the shares underlying the RSU award on the first
anniversary of the grant date and as to an additional 25% of the
shares underlying the RSU award annually thereafter, subject to
each such employee's continued employment on each vesting date.
About ApellisApellis Pharmaceuticals, Inc. is a
global biopharmaceutical company that is committed to leveraging
courageous science, creativity, and compassion to deliver
life-changing therapies. Leaders in targeted C3 therapies, we aim
to develop transformative therapies for a broad range of
debilitating diseases that are driven by excessive activation of
the complement cascade, including those within hematology,
ophthalmology, nephrology, and neurology. For more information,
please visit www.apellis.com.
Apellis Forward-Looking StatementStatements in
this press release about future expectations, plans and prospects,
as well as any other statements regarding matters that are not
historical facts, may constitute “forward-looking statements”
within the meaning of The Private Securities Litigation Reform Act
of 1995. These statements include, but are not limited to,
statements relating to the implications of preliminary clinical
data. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “will,” “would” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including: whether the company’s
clinical trials will be fully enrolled and completed when
anticipated; whether preliminary or interim results from a clinical
trial will be predictive of the final results of the trial; whether
results obtained in preclinical studies and clinical trials will be
indicative of results that will be generated in future clinical
trials; whether pegcetacoplan will successfully advance through the
clinical trial process on a timely basis, or at all; whether the
results of the company’s clinical trials will warrant regulatory
submissions and whether pegcetacoplan will receive approval from
the FDA or equivalent foreign regulatory agencies for GA, PNH, CAD,
C3G, IC-MPGN, ALS or any other indication when expected or at all;
whether, if Apellis’ products receive approval, they will be
successfully distributed and marketed; and other factors discussed
in the “Risk Factors” section of Apellis’ Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on November
2, 2020 and the risks described in other filings that Apellis may
make with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Apellis specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
Investor Contact: Argot
Partnersapellis@argotpartners.com+1 212.600.1902
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Apr 2023 to Apr 2024